electroCore Q2 revenue jumps, but slightly misses estimates

electroCore

06/08/2026 21:52

Overview
Bioelectronic tech firm's Q2 revenue rose 28% yr/yr, slightly missing analyst expectations
Q2 operating income and pretax loss both came in better than analyst expectations
Company raised 2026 revenue growth guidance to over 30% yr/yr

Outlook
electroCore raises 2026 revenue guidance to greater than 30% annual growth over 2025
Company expects to achieve positive Adjusted EBITDA in the third quarter of 2027

Result Drivers
VA CHANNEL GROWTH - Co said revenue growth was primarily driven by continued growth in U.S. prescription sales in the Department of Veterans Affairs channel
QUELL SALES SURGE - Sales of Quell product line, especially Quell Fibromyalgia, grew sharply year-over-year, mostly through the VA
TRUVAGA SPEND CUTS - Truvaga revenue grew year-over-year but declined sequentially as co reduced spending in response to higher media pricing

Company press release: ID:nGNXbjy33J

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Miss*
$9.45 mln
$9.49 mln (5 Analysts)
Q2 Net Loss
 
$3.06 mln
 
Q2 Operating Income
Beat
-$2.77 mln
-$3.42 mln (4 Analysts)
Q2 Pretax Loss
Beat
$3.06 mln
$3.62 mln (4 Analysts)
Q2 Gross Profit
 
$8.18 mln
 
Q2 Operating Expenses
 
$10.95 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Reuters Recommended Reads
Aug 3 - ClearPoint Neuro Q2 revenue rises 18% but misses estimates
Aug 6 - Teleflex Q2 revenue rises 29%, beats analyst estimates
Aug 3 - SI-BONE Q2 revenue beats estimates, raises 2026 revenue outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)